In his debut blog, Nick Meader tackles a huge umbrella review of youth mental health interventions, which presents the efficacy and acceptability of 72 different approaches to help children and young people.
[read the full story...]
Dolly Sud writes her debut elf blog on a recent retrospective analysis, which compares dose changes of risperidone and aripiprazole with patients’ individual genotype.
[read the full story...]
Rudiger Pittrof and Elana Covshoff from SHRINE (Sexual and Reproductive Health Rights, Inclusion and Empowerment) explore a recent review, which looks at the impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management.
[read the full story...]
Carmine Pariante is positive about a recent systematic review and meta-analysis of antidepressants for the treatment of depression in schizophrenia.
[read the full story...]
Samei Huda mulls over a recent RCT on the effects of older and newer antipsychotics on quality of life in schizophrenia. The study finds a different result to the 10-year old CUTLASS trial; namely that second generation antipsychotics may be superior to first generation antipsychotics in terms of improving quality of life for people with schizophrenia.
[read the full story...]
Sarsha Wilson publishes her debut blog about a recent RCT on the efficacy, safety and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in later life.
[read the full story...]
Individuals with severe mental illness (SMI) have shortened life expectancies compared to the general population. This is partly down to higher rates of chronic physical illness. Cardiovascular disease (CVD) is the leading cause of death among patients using mental health services. It is assumed that interventions used to reduce CVD are similarly effective in patients with [read the full story…]
